Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
28 März 2023 - 4:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MARCH 2023
COMMISSION FILE NUMBER 001-34041
| Evotec SE |
| (Translation of registrant’s name into English) |
Essener Bogen 7
22419 Hamburg
Germany
Tel: +49 40 560810
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
On March 28, 2023, Evotec SE (the “Company”) announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE:BMY), originally signed in 2016. The ad hoc release is attached hereto as Exhibit 99.1. An accompanying press release is attached hereto as Exhibit 99.2.
SIGNATURE
Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Evotec SE | |
| | | | |
| By: | /s/ Enno Spillner | |
| | | Name: Enno Spillner | |
| | | Title: Chief Financial Officer | |
| Date: March 28, 2023 | | | |
EXHIBIT INDEX
Evotec (NASDAQ:EVO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Evotec (NASDAQ:EVO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
